Advancing safe, tolerable and durable medicines for metabolic diseases

Approach

CinFina Pharma, a CinRx portfolio company, is advancing a pipeline of high-impact monotherapies and combination treatments for people with obesity.

GLP-1’s have made significant progress to help patients with obesity achieve weight loss goals and improve associated comorbidities. The CinFina pipeline is designed to overcome limitations of current GLP-1 therapy and expand treatment options to enhance the tolerability, quality and durability of weight loss with a focus on body composition and preservation of lean body mass. Our portfolio includes:

Gut peptide monotherapies, GDF-15 and PYY_3-36, to be used independently or co-administered with other obesity therapies such as GLP-1 receptor agonists.
Next-generation, dual agonists of GDF-15 + GLP-1 and PYY_3-36 + GLP-1 designed to deliver additive or synergistic effects, giving patients the option to receive two drugs with different mechanisms of action in a single injection.

GLP-1’s have proven to be effective, however, there remain multiple opportunities to improve the quality of weight loss.

10% of adults with obesity are currently using or have used anti-obesity therapies
[KFF.org Poll 2023]
50% of obese patients with diabetes discontinue GLP-1 therapies within 1 year and 70% discontinue within 2 years
[Wilding JP et al, NEJM, 2021]
40% loss in lean body mass observed with GLP-1 therapy
[Weiss T et al, BMJ Open Diab Res Care 2022]
66% of weight is regained within a year post-GLP-1 therapy
[Wilding JP et al, Diab Obesity and Metab, 2022]

Pipeline

Candidate

Pre-Clinical Phase 1 Phase 2 Phase 3

CIN-109

CIN-109 is a Phase 2, growth differentiation factor 15 (GDF-15) analog developed as a monotherapy and co-administration agent for obesity. GDF-15 is a centrally acting member of the TGF-β superfamily. Through its interaction with the GFRAL receptor, GDF-15’s anti-obesity effects include a decrease of appetite and the maintenance of energy expenditure.

Phase 1 SAD & MAD studies have been completed. A Phase 2 study evaluating CIN-109 with and without semaglutide will be initiated in 2024.

CIN-110

CIN-110 is a long-acting PYY3-36 analog developed as a monotherapy and co-administration agent for obesity. PYY is a gut-derived peptide that selectively binds and activates the neuropeptide Y2 receptor (Y2R) centrally to reduce appetite while improving glucose homeostasis and insulin sensitivity.

The IND for CIN-110 has been cleared by the U.S. Food and Drug Administration (FDA) and a single ascending dose study of CIN-110 is ongoing.

CIN-209

CIN-209 is a dual agonist consisting of a novel GLP-1 covalently linked with a GDF-15 analog. The combination of these two mechanisms of action will enhance the weight loss of the GLP-1, allow for better tolerability when the two drugs are given in lower doses and will improve the quality of weight loss by preserving lean mass.

Pre-clinical development to support an IND filing is ongoing.

CIN-210

CIN-210 is a dual-agonist consisting of a novel GLP-1 covalently linked with a PYY3-36 analog. The combination of these two mechanisms of action will provide a synergistic effect on weight loss and thereby can be used in lower doses to improve tolerability.

Pre-clinical development to support an IND filing is ongoing.

Cinfina Team

CinFina Pharma is a CinRx portfolio company. CinRx deploys a hub-and-spoke approach in advancing its portfolio of multiple biotechnology companies, each rapidly developing high-impact medicines for patients in need.

The CinFina team consists of the scientific, technical and clinical development experts from its central team at CinRx Pharma.

For more information about the CinRx model, to meet the team or to view the entire portfolio, visit CinRx.com.